Surya Ganguli, a neural dynamics researcher at Stanford University, joins Vijay Pande to discuss interpretability in AI, and the potential for AI to become a 'clear box'. They explore the future of AI-augmented humans and the importance of understanding AI systems. They also touch on the cost of training AI models, meta learning, regulatory frameworks, and the need for interdisciplinary collaboration.

Daphne Koller, founder and CEO at insitro and AI expert, discusses the use of AI in life sciences, including the POSH approach for potential therapeutic interventions. They also explore the power of AI in analyzing cellular images and clinical data, and the challenges of merging biology and ML AI.

Today's episode features Aviv Regev, PhD, the Head and Executive VP of Genentech Research and Early Development, and founding co-chair of the Human Cell Atlas. She is joined by Vijay Pande of Bio + Health.Together, Aviv and Vijay talk about how Aviv's love of both abstractions and details led her to biology, how CRISPR really set the field into motion, and how AI could transform the process of biological and medical discovery.

Andrew Ng, a distinguished authority in the field of AI, discusses integrating AI into different areas of our lives and the concerns of AI becoming a dominant species. They explore early work in AI, multimodal language models, and the intersection of AI and startups. They also discuss the progress and limitations in AI vision, job displacement caused by AI, and potential solutions for navigating the impact of automation on jobs.

Dr. Carl June discusses his pioneering work in CAR T therapy, his journey into T cell immunology, the challenges in treating solid tumors, and the potential solutions in cancer treatment.

Dan Nomura, distinguished professor at UC Berkeley and advisory partner at a16z Bio+Health, discusses his work in chemical biology and drug discovery. He shares his experience starting companies, collaborating with pharmaceutical companies, and the challenges of developing therapeutics. The podcast also explores the definition of chemical biology, the future of chemoproteomics, and the benefits of academic-pharma collaborations.

In this exclusive conversation from the Bio + Health BUILD summit, founding partner Ben Horowitz sits down with general partner Jorge Conde. They discuss everything from the inspiration behind Ben’s book The Hard Thing About Hard Things, how the open Internet was secured, the difference between wartime and peacetime CEOs, scaling culture, and understanding how bio and healthcare differs from other forms of technology.

Lloyd B. Minor, Dean of Stanford Medical School, discusses the potential of AI in medicine and its impact on medical education. They cover the integration of medicine with science and technology, AI in healthcare delivery, advice for undergrads interested in medicine, and maintaining resilience for mental health.

Margaret McKenna, Healthtech CTO, talks about her journey into tech and healthcare industries, challenges of building from scratch vs using external vendors, difficulties faced by CTOs in healthcare sector, and the need for innovation in healthcare product companies. They also discuss addressing consumer engagement and risk delegation in healthcare.

Together, Vijay and Zak talked about having been through AI winters and hype cycles before, and why they think this time could be different. They also talked about how AI could revolutionize the healthcare model — what Zak calls the “flipped clinic.”Join Zak and Vijay as they talk about how AI could flip the clinic, how foundation models could quickly transform the discovery and development of drugs, and how Zak thinks about the future.